Disease burden of extensively drug-resistant tuberculosis attributable to tobacco in China from 1993 to 2021
MA Xiao1, NING Shilong2
1. Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang 321000, China; 2. Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang 321000, China
Abstract：Objective To analyze the trends in age-standardized mortality rate (ASMR) and age-standardized disability-adjusted life year rate (ASDR) of extensively drug-resistant tuberculosis (XDR-TB) attributable to tobacco in China from 1993 to 2021, and to evaluate their age, period, and cohort effects, so as to provide the evidence for formulating targeted prevention and control strategies for XDR-TB. Methods Data on the disease burden of XDR-TB attributable to tobacco in China from 1993 to 2021 were collected from the Global Burden of Disease (GBD) 2021 database, including ASMR and ASDR. The estimated annual percentage change (EAPC) was calculated to analyze trends in ASMR and ASDR from 1993 to 2021. An age-period-cohort model was employed to analyze age, period, and cohort effects on ASMR and ASDR. Results From 1993 to 2021, the ASMR of XDR-TB attributable to tobacco in China showed an overall declining trend (EAPC=-2.412%, P<0.05), while the trend in ASDR was not statistically significant (EAPC=3.971%, P>0.05). The age-period-cohort model analysis revealed that both the ASMR and ASDR initially increased and then decreased with advancing age. The highest ASMR was observed in the age group of 75-<80 years, at 0.084 5/105, and the highest ASDR was observed in the age group of 70-<75 years, at 1.680 1/105. The lowest ASMR and ASDR were both found in the age group of 95-<100 years, at 0.039 0/105 and 0.365 2/105, respectively. Using the 2003-2007 period as the reference, the risks of mortality and disability showed an initial increase followed by a decrease over time. The risks peaked in the 2003-2007 period and subsequently declined, reaching their lowest point in the 2013-2017 period, with corresponding RR values of 0.369 (95%CI: 0.289-0.473) for mortality and 0.382 (95%CI: 0.359-0.408) for disability. Using the 1943-1947 birth cohort as the reference, the risks of mortality and disability exhibited a declining trend with later birth years. The lowest risk was observed in the 1973-1977 birth cohort for mortality, with an RR value of 0.534 (95%CI: 0.311-0.917), and in the 1983-1987 birth cohort for disability, with an RR value of 0.446 (95%CI: 0.386-0.516). Conclusions From 1993 to 2021, the overall disease burden of XDR-TB attributable to tobacco in China demonstrated a declining trend. The disease burden was more pronounced among the elderly, and the risks of mortality and disability showed an initial rise followed by a decline across periods, exhibiting a consistent downward trend across successive birth cohorts.
马宵, 宁士龙. 1993—2021年中国归因于烟草的广泛耐药结核病疾病负担分析[J]. 预防医学, 2025, 37(12): 1266-1271.
MA Xiao, NING Shilong. Disease burden of extensively drug-resistant tuberculosis attributable to tobacco in China from 1993 to 2021. Preventive Medicine, 2025, 37(12): 1266-1271.
[1] World Health Organization.Tuberculosis:extensively drug-resistant tuberculosis(XDR-TB)[EB/OL].[2025-11-18] .https://www.who.int/zh/news-room/questions-and-answers/item/tuberculosis-extensively-drug-resistant-tuberculosis-(XDR-TB). [2] MIRZAYEV F,VINEY K,LINH N N,et al.World Health Organization recommendations on the treatment of drug-resistant tuberculosis,2020 update[J/OL].Eur Respir J,2021,57(6)[2025-11-18] .https://doi.org/10.1183/13993003.03300-2020. [3] JIN C,WU Y T,CHEN J P,et al.Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China:a systematic review and meta-analysis[J].J Glob Antimicrob Resist,2024,38:292-301. [4] LUGG S T,SCOTT A,PAREKH D,et al.Cigarette smoke exposure and alveolar macrophages:mechanisms for lung disease[J].Thorax,2022,77(1):94-101. [5] WILLEMSE D,MOODLEY C,MEHRA S,et al.Transcriptional response of Mycobacterium tuberculosis to cigarette smoke condensate[J/OL].Front Microbiol,2021,12[2025-11-18] .https://doi.org/10.3389/fmicb.2021.744800. [6] 王辰,肖丹,池慧.《中国吸烟危害健康报告2020》概要[J].中国循环杂志,2021,36(10):937-952. WANG C,XIAO D,CHI H.2020 Report on Health Hazards of Smoking in China:an updated summary[J].Chin Circ J,2021,36(10):937-952.(in Chinese) [7] 陈俊虎,刘志昌,张贤昌,等.DOTS策略下广东省2010—2013年结核病防治效果[J].热带医学杂志,2017,17(9):1254-1257. CHEN J H,LIU Z C,ZHANG X C,et al.Prevention and control of tuberculosis in Guangdong Province under DOTS strategy from 2010 to 2013[J]. J Trop Med,2017,17(9):1254-1257.(in Chinese) [8] 邱德超,宋福建,冯振宁,等.我国地方控烟政策:基于政策文本的内容分析[J].现代预防医学,2021,48(4):681-684. QIU D C,SONG F J,FENG Z N,et al.Local tobacco control policies in China based on text analysis[J].Mod Prev Med,2021,48(4):681-684.(in Chinese) [9] IRFAN M.Post-tuberculosis pulmonary function and noninfectious pulmonary disorders[J].Int J Mycobacteriol,2016,5(Suppl. 1):57. [10] GANDHI N R,BRUST J C M,SHAH N S.A new era for treatment of drug-resistant tuberculosis[J/OL].Eur Respir J,2018,52(4)[2025-11-18] .https://doi.org/10.1183/13993003.01350-2018. [11] ZHOU R F,ZHENG T L,LUO D X,et al.Drug resistance characteristics of Mycobacterium tuberculosis isolates obtained between2018 and 2020 in Sichuan,China[J/OL].Epidemiol Infect,2022,150[2025-11-18] .https://doi.org/10.1017/S0950268822000127. [12] 凌红,汪娜,宋琴,等.2009—2023年黄浦区肺结核流行特征和时空聚集性分析[J].预防医学,2025,37(9):937-940. LING H,WANG N,SONG Q,et al.Epidemiological characteristics and spatio-temporal clustering of pulmonary tuberculosis in Huangpu District from 2009 to 2023[J].China Prev Med J,2025,37(9):937-940.(in Chinese) [13] LI Y,LI H,TANG L R,et al.Global burden and cross-national inequalities of tobacco-attributable cancers in adults aged 40 and above,1990-2021:a population-based study[J/OL].Front Oncol,2025,15[2025-11-18] .https://doi.org/.10.3389/fonc.2025.1631356. [14] YANG L,XING Y,GAO X,et al.Burden of ageing spectrum of diseases in China,1990-2021:a systematic analysis of global burden of disease study 2021[J/OL].Front Public Health,2025,13[2025-11-18] .https://doi.org/.10.3389/fpubh.2025.1611901. [15] CHAN K H,XIAO D,ZHOU M,et al.Tobacco control in China[J].Lancet Public Health,2023,8(12):1006-1015. [16] 许铭. 抗击艾滋病、结核病和疟疾全球基金在全球卫生发展中的作用及与中国的合作[J].中国血吸虫病防治杂志,2023,35(2):116-120. XU M.The role of the global fund to fight AIDS,tuberculosis and malaria in the development of global health and its collaboration with China[J].Chin J Schisto Control,2023,35(2):116-120.(in Chinese) [17] 张慧,成君,屈燕,等.“三新一加强”结核病综合防治服务模式的验证、示范与推广:中国国家卫生健康委员会-比尔及梅琳达·盖茨基金会结核病项目[J].中国防痨杂志,2021,43(8):757-760. ZHANG H,CHENG J,QU Y,et al.Validation,demonstration,and promotion of the“Three Technical Innovations Plus Health System Strengthening”comprehensive tuberculosis prevention and control model:the China National Health Commission-Bill and Melinda Gates Foundation Tuberculosis Project[J].Chin J Antituberc,2021,43(8):757-760.(in Chinese) [18] TANG S J,YAO L,HAO X H,et al.Efficacy,safety and tolerability of linezolid for the treatment of XDR-TB:a study in China[J].Eur Respir J,2015,45(1):161-170.
